LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

KemPharm Inc

Closed

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

33M

-3.1M

Sales

8.4M

20M

EPS

-0.06

Profit margin

-15.19

Employees

59

EBITDA

11M

-5.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+159.01% upside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

62M

487M

Previous open

0

Previous close

0

KemPharm Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Feb 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

5 Aug 2024, 11:25 UTC

Major Market Movers

Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol

Peer Comparison

Price change

KemPharm Inc Forecast

Price Target

By TipRanks

159.01% upside

12 Months Forecast

Average 22.43 USD  159.01%

High 25 USD

Low 19 USD

Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$